Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05908253 · ClinicalTrials.gov registry record · NA

Toward a Generalizable Closed-loop Neurofeedback-based BCI for Attention Training

A NA study of Neurofeedback, sponsored by University of Rhode Island.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT05908253 is a NA study of Neurofeedback that has completed, run by University of Rhode Island. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05908253, a NA study of Neurofeedback, has completed, sponsored by University of Rhode Island.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The proposed study accelerates the translational aspect of neurofeedback-based attention training using novel technologies, algorithms, and neuromarkers. The presented brain training intervention and approaches will not only be applicable to attention remedy in patients with attention deficits but also can be applied to treatment of other neurocognitive (mental) disorders such as anxiety, depression, and addiction.

Conditions Studied

Interventions

  • BEHAVIORAL sham neurofeedback
  • BEHAVIORAL nonadaptive neurofeedback
  • BEHAVIORAL adaptive neurofeedback

Study Locations (1)

Rhode Island

  • University of Rhode Island - Kingston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2023-12-16
Est. Completion 2024-04-30
Phase NA

Sponsor

University of Rhode Island

29 total trials

What the Registry Record Tells You About NCT05908253

The ClinicalTrials.gov registry entry for NCT05908253 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rhode Island, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neurofeedback appearing as the primary indexed condition, and to 3 interventions - of which sham neurofeedback is the first listed.

NCT05908253 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT05908253 about?

NCT05908253 is a clinical study titled "Toward a Generalizable Closed-loop Neurofeedback-based BCI for Attention Training". The proposed study accelerates the translational aspect of neurofeedback-based attention training using novel technologies, algorithms, and neuromarkers. The presented brain training intervention and approaches will not only be applicable to attention remedy in patients with attention deficits but a...

What is the current status of trial NCT05908253?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2023-12-16. Estimated completion is 2024-04-30.

What conditions does trial NCT05908253 study?

This clinical trial studies the following conditions: Neurofeedback.

What interventions are being tested in trial NCT05908253?

The interventions under investigation include: sham neurofeedback (BEHAVIORAL), nonadaptive neurofeedback (BEHAVIORAL), adaptive neurofeedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT05908253?

This trial is sponsored by University of Rhode Island, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05908253 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurofeedback

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.